SAEID NEKOUEIAN: Open Payments
NPI 1356955462 · SAN ANTONIO, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,156 in 37 payments from 8 companies in 2025. Trend: 2023 $1,840 · 2024 $2,306 · 2025 $2,156
Food & beverage: $2,156
| Company | Payments | Amount |
|---|---|---|
| Teva Pharmaceuticals USA, Inc. | 6 | $523 |
| E.R. Squibb & Sons, L.L.C. | 11 | $448 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 7 | $333 |
| ABBVIE INC. | 5 | $289 |
| Neurocrine BioSciences, Inc. | 5 | $202 |
| Axsome Therapeutics, Inc. | 1 | $125 |
| Otsuka America Pharmaceutical, Inc. | 1 | $120 |
| Vanda Pharmaceuticals Inc. | 1 | $115 |
Products named: UZEDY, COBENFY, CAPLYTA, VRAYLAR, INGREZZA, Auvelity, ABILIFY ASIMTUFII, FANAPT.
Industry payments across TX — which companies pay providers there.
